Effects of combination of orlistat and micronised fenofibrate on lipid profile in overweight and obese patients with metabolic syndrome

被引：0
|
作者：
Filippatos, TD
Kiortsis, DN
Tselepis, AD
Athyros, V
Elisaf, MS
机构：
[1] Univ Ioannina, Dept Internal Med, Sch Med, GR-45110 Ioannina, Greece
[2] Univ Ioannina, Physiol Lab, Sch Med, GR-45110 Ioannina, Greece
[3] Univ Ioannina, Dept Chem, Biochem Lab, GR-45110 Ioannina, Greece
[4] Aristotle Univ Thessaloniki, Atherosclerosis Unit, Hippocrat Hosp, GR-54006 Thessaloniki, Greece
来源：
ATHEROSCLEROSIS SUPPLEMENTS | 2005年 / 6卷 / 01期
关键词：
D O I：
10.1016/S1567-5688(05)80424-6
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：107 / 107
页数：1
相关论文
共 50 条
  • [1] Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study
    Filippatos, TD
    Kiortsis, DN
    Liberopoulos, EN
    Georgoula, M
    Mikhailidis, DP
    Elisaf, MS
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (12) : 1997 - 2006
  • [2] Effects of orlistat and fenofibrate combination on LDL phenotype in overweight and obese patients with metabolic syndrome. The fenorli study
    Filippatos, T. D.
    Kiortsis, D. N.
    Gazi, I.
    Liberopoulos, E. N.
    Georgoula, M.
    Elisaf, M. S.
    Tselepis, A. D.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 553 - 553
  • [3] Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study
    Florentin, M.
    Liberopoulos, E. N.
    Filippatos, T. D.
    Kostara, C.
    Tselepis, A.
    Mikhailidis, D. P.
    Elisaf, M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (16) : 2741 - 2750
  • [4] Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome
    Filippatos, Theodosios D.
    Tsimihodimos, Vasilis
    Kostapanos, Michael
    Kostara, Christina
    Bairaktari, Eleni T.
    Kiortsis, Dimitrios N.
    Elisaf, Moses S.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2008, 2 (04) : 279 - 284
  • [5] EFFECTS OF FENOFIBRATE AND ORLISTAT, ALONE OR IN COMBINATION, ON PLASMA VISFATIN LEVELS IN SUBJECTS WITH METABOLIC SYNDROME
    Derdemezis, C. S.
    Filippatos, T. D.
    Nakou, E. S.
    Georgoula, M.
    Kiortsis, D. N.
    Tselepis, A. D.
    Elisaf, M. S.
    ATHEROSCLEROSIS SUPPLEMENTS, 2008, 9 (01) : 133 - 134
  • [6] Efficacy of orlistat in overweight and obese patients with metabolic syndrome and its effects on the risk of coronary heart disease
    Caterson, I
    Guy-Grand, B
    Hill, J
    DIABETOLOGIA, 2004, 47 : A14 - A15
  • [7] Orlistat improves all components of the metabolic syndrome in overweight and obese patients on two diets
    Jacob, S
    Ziegler, O
    Toplak, H
    INTERNATIONAL JOURNAL OF OBESITY, 2004, 28 : S154 - S154
  • [8] Metabolic syndrome in obese patients and atherogenic lipid profile
    Marinez-Triguero, M. L.
    Jarabo-Bueno, M. M.
    Lopez-Ruiz, A.
    Jover, A.
    Sola-Izquierdo, E.
    Hernandez-Mijares, A.
    ATHEROSCLEROSIS SUPPLEMENTS, 2007, 8 (01) : 177 - 177
  • [9] The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome
    Filippatos, T. D.
    Liberopoulos, E. N.
    Kostapanos, M.
    Gazi, I. F.
    Papavasiliou, E. C.
    Kiortsis, D. N.
    Tselepis, A. D.
    Elisaf, M. S.
    DIABETES OBESITY & METABOLISM, 2008, 10 (06): : 476 - 483
  • [10] Improvement of glycemic control with orlistat in overweight and obese patients with metabolic syndrome and type 2 diabetes
    Hollander, P
    Rissanen, A
    Rabbia, M
    Hauptman, J
    Boldrin, M
    DIABETES, 2003, 52 : A557 - A557
12345